

Applicant : B. Jack Longley
Serial No.: 09/980,572
Filed : October 31, 2001
Page 2

differs from the parent application. In response, applicant directs the Examiner's attention to the following pages and lines of the instant application, *inter alia*, which disclose information which differs from that in the parent application:

- a. page 4, lines 18-36;
- b. page 5, lines 14-19;
- c. pages 9 and 10, lines 35-38 and lines 1-28, respectively;
- d. pages 12 and 13, lines 33-38 and lines 1-11, respectively;
- e. pages 15 and 16, lines 37-38 and lines 1-9, respectively;
- f. page 31, lines 26-28 and pages 32 and 33;
- g. page 43, lines 21-28;
- h. pages 46 and 47, lines 27-38 and lines 1-7, respectively; and
- i. page 50, lines 13-38 and pages 51-55.

In the Office Action, the Examiner restricted pending claims 1-9, 12, 13, 38, 43, 44, 53, 54, 61, 65, 72 and 89 to one of the following allegedly distinct inventions under 35 U.S.C. §121 and §372 as follows:

- I. Claims 1-9, 12, 13 and 38, drawn to a method of preventing or treating disorders;
- II. Claim 43, drawn to a method of desensitizing;

Applicant : B. Jack Longley
Serial No.: 09/980,572
Filed : October 31, 2001
Page 3

III. Claims 44, 54 and 65, drawn to a method of identifying compounds; and

IV. Claims 53, 61, 72 and 89, drawn to compositions.

In addition, the Examiner asserted that Group I, as set forth above, contains claims directed to more than one species of the generic invention. The species are as follows: dermatitis, hyperpigmentation, asthma, cutaneous inflammation, bronchospasm, mastocytosis, urticaria, hypersensitivity reactions, airway inflammation, interstitial cystitis, tumors, and contraception. The Examiner indicated that the reply to this action must elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The Examiner also indicated that the reply must identify the claims readable on the elected species.

In response to this restriction requirement, applicant hereby elects, with traverse, Group I, claims 1-9, 12, 13 and 38, for prosecution at this time. Applicant also elects the species of contact dermatitis.

In addition, applicant requests that upon the allowance of a generic claim, consideration of claims to additional species which are written in dependent form be considered.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned

Applicant : B. Jack Longley
Serial No.: 09/580,572
Filed : October 31, 2001
Page 4

attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with this Communication. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Alan J. Morrison
Reg. No. 37,399

7/22/07
Date